Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Waning Humoral Immune Response Following the Third and Fourth SARS-COV-2 Vaccine: A Cohort Study in Healthcare Workers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford, UK : Wiley, c2007-
    • Subject Terms:
      Health Personnel* ; Antibodies, Viral*/blood ; COVID-19*/prevention & control ; COVID-19*/immunology ; COVID-19 Vaccines*/immunology ; COVID-19 Vaccines*/administration & dosage ; SARS-CoV-2*/immunology ; BNT162 Vaccine*/immunology ; BNT162 Vaccine*/administration & dosage ; Immunization, Secondary* ; Immunity, Humoral*; Humans ; Male ; Female ; Adult ; Prospective Studies ; Middle Aged ; Turkey ; Cohort Studies ; Vaccination
    • Abstract:
      Background: This study is aimed at providing information about the timing of booster doses and antibody kinetics in healthcare workers.
      Methods: This research extends a prospective cohort study conducted at Dokuz Eylul University Hospital in Turkey, covering the period from March 2021 to December 2021. During this timeframe, the antibody levels of the health workers were measured at four different time points. The associations of antibody levels with gender, age, occupation, body mass index (BMI), chronic disease, and smoking were analyzed.
      Results: There was a significant difference between antibody levels in all four blood draws (p < 0.001). Antibody levels decreased in both those vaccinated with BNT162b2 (p < 0.001) and those vaccinated with CoronaVac (p = 0.002) until the fourth blood draw. There was a significant difference between those vaccinated with one and two doses of booster BNT162b2 before the third blood draw (p < 0.001), which continued at the fourth blood draw (p < 0.001). The antibody levels of those with an interval of 41-50 days between two vaccinations decreased significantly at the fourth blood draw (p < 0.001).
      Conclusions: This study provides insight into the dynamics and persistence of antibody response after additional COVID-19 vaccine doses among healthcare workers. The longer the interval between booster doses may result in greater antibody levels being maintained over time, allowing for longer durations of protection.
      (© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
    • References:
      Lancet. 2021 Dec 18;398(10318):2258-2276. (PMID: 34863358)
      Lancet Infect Dis. 2022 Jul;22(7):1002-1010. (PMID: 35405090)
      Vaccine. 2022 Jul 30;40(32):4312-4317. (PMID: 35701327)
      N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
      Immunity. 2020 Dec 15;53(6):1281-1295.e5. (PMID: 33296685)
      Lancet Respir Med. 2022 Nov;10(11):1049-1060. (PMID: 35690076)
      Cell. 2021 Nov 11;184(23):5699-5714.e11. (PMID: 34735795)
      Front Immunol. 2021 Nov 30;12:776933. (PMID: 34917089)
      J Med Virol. 2022 May;94(5):2212-2221. (PMID: 35075655)
      JAMA Netw Open. 2022 Jul 1;5(7):e2223090. (PMID: 35862048)
      Psychol Med. 2022 Jan;52(1):195-197. (PMID: 32456735)
      Sci Rep. 2023 Jun 3;13(1):9036. (PMID: 37270632)
      Sci Rep. 2022 Feb 23;12(1):3055. (PMID: 35197495)
      Lancet Reg Health Am. 2022 May;9:100198. (PMID: 35187521)
      Lancet Infect Dis. 2022 Aug;22(8):1131-1141. (PMID: 35550261)
      N Engl J Med. 2021 Oct 21;385(17):1627-1629. (PMID: 34525276)
      Lancet. 2022 Feb 5;399(10324):521-529. (PMID: 35074136)
      Nat Med. 2022 May;28(5):1063-1071. (PMID: 35189624)
      N Engl J Med. 2020 Oct 15;383(16):1544-1555. (PMID: 32722908)
      Immune Netw. 2022 Jun 17;22(4):e31. (PMID: 36081526)
      Lancet. 2022 Mar 5;399(10328):924-944. (PMID: 35202601)
      J Med Virol. 2022 Jan;94(1):35-38. (PMID: 34516026)
      N Engl J Med. 2022 May 5;386(18):1712-1720. (PMID: 35381126)
      NPJ Vaccines. 2022 Jan 27;7(1):14. (PMID: 35087066)
      Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865. (PMID: 35816053)
      Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2211132120. (PMID: 36623200)
      Front Immunol. 2022 May 31;13:863554. (PMID: 35711445)
      Science. 2021 Feb 26;371(6532):916-921. (PMID: 33479118)
      Hum Vaccin Immunother. 2023 Dec 15;19(3):2275445. (PMID: 37964650)
      Korean J Intern Med. 2022 Nov;37(6):1234-1240. (PMID: 36217813)
      N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
      JAMA Netw Open. 2022 Jul 1;5(7):e2223096. (PMID: 35862049)
      N Engl J Med. 2022 Apr 7;386(14):1377-1380. (PMID: 35297591)
      Front Immunol. 2022 Jan 31;13:827306. (PMID: 35173736)
      Vaccines (Basel). 2022 Jul 25;10(8):. (PMID: 35893828)
      N Engl J Med. 2022 Apr 28;386(17):1603-1614. (PMID: 35417631)
      Ann Intern Med. 2020 Jul 21;173(2):120-136. (PMID: 32369541)
    • Grant Information:
      Dokuz Eylul University Department of Scientific Research Projects
    • Contributed Indexing:
      Keywords: COVID‐19; antibody response; booster doses; healthcare workers; vaccine
    • Accession Number:
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
      0 (BNT162 Vaccine)
    • Publication Date:
      Date Created: 20240827 Date Completed: 20240827 Latest Revision: 20250304
    • Publication Date:
      20250304
    • Accession Number:
      PMC11347934
    • Accession Number:
      10.1111/irv.70003
    • Accession Number:
      39189319